UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Impact of HLA type, age and chronic viral infection on peripheral T-cell receptor sharing between unrelated individuals

PloS one, 2021-08, Vol.16 (8), p.e0249484-e0249484

2021

Link zum Volltext

Verfügbarkeit prüfen

TGF-β-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma

Cell stem cell, 2017-11, Vol.21 (5), p.650-664.e8

2017

Link zum Volltext

Verfügbarkeit prüfen

Correction of aberrant growth preserves tissue homeostasis

Nature (London), 2017-08, Vol.548 (7667), p.334-337

2017

Link zum Volltext

Verfügbarkeit prüfen

Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood

PloS one, 2019-03, Vol.14 (3), p.e0213684-e0213684

2019

Link zum Volltext

Verfügbarkeit prüfen

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

Cancer Immunology, Immunotherapy, 2019-04, Vol.68 (4), p.599-608

2019

Link zum Volltext

Verfügbarkeit prüfen

Fibrin-based 3D matrices induce angiogenic behavior of adipose-derived stem cells

Acta biomaterialia, 2015-04, Vol.17, p.78-88

2015

Link zum Volltext

Verfügbarkeit prüfen

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

JCI insight, 2018-07, Vol.3 (13)

2018

Link zum Volltext

Verfügbarkeit prüfen

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Oncoimmunology, 2019-11, Vol.8 (11), p.e1652538-e1652538

2019

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e000847

2020

Link zum Volltext

Verfügbarkeit prüfen

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A477-A477

2021

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002812

2021

Link zum Volltext

Verfügbarkeit prüfen

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE‐CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e1004207-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

RNAi in the mouse: rapid and affordable gene function studies in a vertebrate system

Wiley interdisciplinary reviews. Developmental biology, 2015-01, Vol.4 (1), p.45-57

2015

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of tubulogenesis and endothelial phenotype expression by MSCs

Microvascular research, 2015-05, Vol.99, p.26-35

2015

Link zum Volltext

Verfügbarkeit prüfen

Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing

Frontiers in immunology, 2018-02, Vol.9, p.280-280

2018

Link zum Volltext

Verfügbarkeit prüfen

Three-dimensional image quantification as a new morphometry method for tissue engineering

Tissue engineering. Part C, Methods, 2012-07, Vol.18 (7), p.507

2012

Link zum Volltext

Verfügbarkeit prüfen

Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8021-8021

2022

Link zum Volltext

Verfügbarkeit prüfen

Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2541-2541

2019

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood, 2021-11, Vol.138 (Supplement 1), p.3834-3834

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20005-e20005

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3864: A single-center retrospective study of the immune landscape in patients with untreated liposarcoma (LS) with long-term follow-up

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3864-3864

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of HLA type, age and chronic viral infection on peripheral T-cell receptor sharing between unrelated individuals

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

TGF-β-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Correction of aberrant growth preserves tissue homeostasis

Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

Fibrin-based 3D matrices induce angiogenic behavior of adipose-derived stem cells

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE‐CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

RNAi in the mouse: rapid and affordable gene function studies in a vertebrate system

Mechanisms of tubulogenesis and endothelial phenotype expression by MSCs

Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing

Three-dimensional image quantification as a new morphometry method for tissue engineering

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy

Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs)

Abstract 3864: A single-center retrospective study of the immune landscape in patients with untreated liposarcoma (LS) with long-term follow-up

Suchergebnisse filtern